Published 16 January 2025

This call consists of prioritized health technology topics that underwent clinical assessment under the HTA general track and are proceeding to economic assessment which includes economic evaluation (EE), budget impact analysis (BIA), and household financial impact (HFI) analysis to assess both the value for money of a health technology and its affordability or the feasibility of publicly funding the health technology relative to the Philippine context.

HTA Topics for Economic Assessment

For Cost-Effectiveness/Utility Analysis (CEA/CUA) + Budget Impact Analysis (BIA) + Household Financial Impact (HFI) Analysis

1. Ranibizumab, Aflibercept, and Dexamethasone as first-line treatment for Diabetic MacularEdema (DME)
2. Ranibizumab compared to Dexamethasone as first-line treatment for Macular Edema Secondary to Retinal Vein Occlusion (ME-RVO)
3. Rapid-acting Insulin Analogs (insulin aspart, insulin lispro, insulin glulisine) compared with regular insulin among Type 1 Diabetes Mellitus (T1DM) patients on basal insulins (i.e., neutral protamine Hagedorn (NPH) or long-acting insulins (LAIs))
4. Rapid-acting Insulin Analogs (insulin aspart, insulin lispro, insulin glulisine) compared with regular insulin among Type 2 Diabetes Mellitus (T2DM) patients on non-insulin medications or basal insulins with or without other medications
5. Ivabradine in addition to standard of care (SOC) (i.e., beta-blockers) in comparison to SOC alone for adult patients aged 19 years old and above with chronic heart failure and with chronic stable angina or, with resting heart rate (HR) > 70 beats per minute (bpm) who are in sinus rhythm, despite being on optimized guideline-directed medical therapy (GDMT), or when GDMT is contraindicated
6. Ticagrelor 60 mg (alone or in combination with aspirin) compared with aspirin alone or clopidogrel (alone or in combination with aspirin) for adult patients with a history of myocardial infarction at least one year ago and a high risk of developing a thrombotic event
7. Tirofiban in combination with heparin compared to usual care [e.g., unfractionated or low-molecular weight heparin (alone), aspirin, clopidogrel] among patients aged > 19 years old with coronary ischemic syndromes (CIS) undergoing coronary angioplasty or atherectomy
8. Tirofiban in combination with heparin compared to usual care [e.g., unfractionated or low-molecular weight heparin (alone), aspirin, clopidogrel] among patients aged > 19 years old with Non-ST Elevation Acute Coronary Syndrome (NSTE-ACS) including Non-ST Elevation Myocardial Infarction (NSTEMI) or Unstable Angina (UA)

For Cost-Minimization Analysis (CMA) + BIA + HFI Analysis

9. Ranibizumab compared to Aflibercept as first-line treatment for Wet Age-related Macular Degeneration (wAMD)
10. Paliperidone palmitate 3-months (PP3M) compared to Paliperidone palmitate 1-month (PP1M) among adult patients with schizophrenia who have been adequately treated with PP1M for at least four months

For Model-based CMA + BIA + HFI Analysis

11. Dipeptidyl peptidase-4 (DPP-4) inhibitors compared to sulfonylureas or SGLT2 inhibitors for adult type 2 diabetes mellitus (DM) patients inadequately controlled on metformin monotherapy

For interested researchers, kindly take note of the following important dates:

• Deadline of expression of interest: 30 January 2025 (Thursday)
• Deadline for submission of requirements: 10 working days from the submission of the expression of interest

Submissions shall be sent to htaresearch@dost.gov.ph

Kindly see the call guide and Terms of Reference for more info:

Call Guide: